ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~"؈ ~~ ؈ ~~8#܈ ~~4#܈ ~~3#܈ ~~<#܈ ~~7#܈ ~~83ffff̙̙3f3fff3f3f33333f33 L NA NA (1)i& Balance SheetBIncome Statement]\ Cash Flows9xNOTE 4 INVENTORY"NOTE 5 OTHER CURRENT ASSETSËNOTE 6 FIXED ASSETS NET@NOTE 7 INTANGIBLE ASSETS&#NOTES TO UNAUDITED CONSOLIDATED&NOTES TO UNAUDITED CONSOLID (1)&CNOTE 8 OTHER CURRENT LIABILITIE NOTE 9 NET LOSS PER SHARE&3NOTES TO UNAUDITED CONSOLID (2)&NOTES TO UNAUDITED CONSOLID (3)&NOTES TO UNAUDITED CONSOLID (4)Research and Development&!Research and Development ExpensF!Results of Operations .Results of Operations (1) :Results of Operations (2)&HLiquidity and Capital ResourcesRItem 6 ExhibitsVc SIGNATURESm Exhibit 311v Exhibit 312 l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } 6} !      TherapeuticsMD, Inc. 10-Q 05/07/2018 N/A!Large accelerated filer ?Accelerated filer ? Non-accelerated filer ?# Smaller reporting company ?5 -(Do not check if a smaller reporting company)! Emerging growth company ?  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$Z,{7wO=PF0*8X> @  l  2%  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NA Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } $ } y } :} $ }  2     TherapeuticsMD, Inc. 10-Q 05/07/2018 N/A-%THERAPEUTICSMD, INC. AND SUBSIDIARIES INDEX          Page& PART I - FINANCIAL INFORMATION       Item. 1Financial Statements/'Consolidated Balance Sheets as of March~ 2*31, 2018 (Unaudited) and December 31, 2017-%Consolidated Statements of Operations~ 1)for the Three Months Ended March 31, 2018( (Unaudited) and 2017 (Unaudited)-%Consolidated Statements of Cash Flows~ 1)for the Three Months Ended March 31, 2018( (Unaudited) and 2017 (Unaudited)1)Notes to Unaudited Consolidated Financial~  StatementsItem 2.,$Management?s Discussion and Analysis~ V80of Financial Condition and Results of OperationsD l{J9{?GZ *] !"#$%&'()*+,-./01     !!Item 3.0!(Quantitative and Qualitative Disclosures!~ !"""about Market Risks#####$$Item 4.$Controls and Procedures$~ $%%%%%#&Part II - OTHER INFORMATION&&'''''((Item 1.(Legal Proceedings(~ ()))))**Item 1A.* Risk Factors*~ *+++++,,Item 6.,Exhibits,~ ,-.$/____________________________10)Created by Morningstar Document Research.01(http://documentresearch.morningstar.com/(TW!M|@eYM%=PF0*8X> @:1100//&&   l  6V8B  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1)Income Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } I;} $ } y} $ } y} $ 6                                 TherapeuticsMD, Inc. 10-Q 05/07/2018 Balance SheetMarch 31, 2018December 31, 2017    (Unaudited)     ASSETS         Current Assets:         Cash ~ R  ~ 2O - %Accounts receivable, net of allowance  ~ n7   ~ 5 7/for doubtful accounts of $403,535 and $380,580, respectively Inventory~ "b~ ZOther current assets~ R*7~ ! Total current assets~ .Di~ bE!Fixed assets, net~ ~  Other Assets:Intangible assets, net~ :~ 1Security deposit~ / ~ r| Total other assets~ "~  Total assets~ ZQ~ Z&"-% LIABILITIES AND STOCKHOLDERS? EQUITYCurrent Liabilities:Accounts payable~ ˆ~ !Other current liabilities~ *A<~ 2D l}q-Vnq|! ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 &  Total current liabilities  ~ ɻ   ~ - !!!!!!!!!0"(Commitments and Contingencies - See Note""""""""~ #:$$$$$$$$$%Stockholders? Equity:%%%%%%%%6&.Preferred stock - par value $0.001; 10,000,000&& &?&&& &?&/''shares authorized; no shares issued and( outstanding4),Common stock - par value $0.001; 350,000,000))))))))*shares authorized:.+&216,584,274 and 216,429,642 issued and++~ +"8 +++~ +5 +!,outstanding, respectively"-Additional paid-in capital--~ -){---~ -{-.Accumulated deficit..~ ....~ .B3У.'/ Total stockholders? equity//~ /r6///~ //901 Total liabilities and stockholders? equity0~ 0ZQ00~ 0Z&"012$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/0f rrdwE =PF0*8X> @r5544330000    l  ..U[  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance Sheet Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } 0} $ }  } $ }  } $ .                                 TherapeuticsMD, Inc. 10-Q 05/07/2018Income StatementThree Months Ended   March 31, 2018   March 31, 2017          Revenues, net ~ BO  ~ @           Cost of goods sold  ~ ^&   ~ B(  Gross profit~ 梿~ Operating expenses:*"Sales, general, and administrative~ ~ Ư Research and development~ ~ |%Depreciation and amortization~ ~ % Total operating expenses~ n4~ 4Operating loss~ zn~ & Other incomeMiscellaneous income~ 2~ BAccreted interest ?~ n< Total other income~ 2~  Loss before income taxes~ n.~ ҵD+lzn,h-B($@ @b --,,++&&&&""""     l  0ow  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome StatementNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } C} $ } } $ } } $ 0                                 TherapeuticsMD, Inc. 10-Q 05/07/2018 Cash FlowsThree Months Ended   March 31, 2018   March 31, 2017 , $CASH FLOWS FROM OPERATING ACTIVITIES          Net loss ~ n.  ~ ҵ 0 (Adjustments to reconcile net loss to net        * "cash used in operating activities: Depreciation~ bX~  3+ Amortization of intangible assets~ 6K~ @8 Provision for (recovery of) doubtful accounts~ f~ *" Share-based compensation~ j~ .AV>6 Changes in operating assets and liabilities:( Accounts receivable~ n~ >u# Inventory~ ~ )! Other current assets~ [~ ʆ% Accounts payable~ o~ .& Other current liabilities~ ~J ~ zS-%Net cash used in operating activities~ P~ f6,$CASH FLOWS FROM INVESTING ACTIVITIES Patent costs~ "S~ p" Purchase of fixed assets~ [~ M% Payment of security deposit~ L ?D6lt22<EjGFJB ! " # $ % & ' ( ) * + , - . / - %Net cash used in investing activities  ~ :   ~  !!!!!!!!!,"$CASH FLOWS FROM FINANCING ACTIVITIES""""""""+## Proceeds from exercise of options##~ #f###~ #ڼ #,$$ Proceeds from exercise of warrants$$ $?$$$~ $%$%%%%%%%%%1&)Net cash provided by financing activities&&~ &f&&&~ &Z&'''''''''(Decrease in cash((~ ("YH(((~ (Zִ(!)Cash, beginning of period))~ )2O)))~ )V4\)*Cash, end of period*~ *R**~ * *+,$-____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$,koIDXdXL$=PF0*8X> @R //..--****     l  '  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } } $                   TherapeuticsMD, Inc. 10-Q 05/07/2018NOTE 4 INVENTORY March 31, December 31,  ~   ~  Finished product ~ "b  ~ Z   TOTAL INVENTORY ~ "b  ~ Z   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&@znQ=PF0*8X> @Z        l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } <(} $ }  } $ }  } $                      TherapeuticsMD, Inc. 10-Q 05/07/2018#NOTE 5 OTHER CURRENT ASSETS March 31, December 31,  ~   ~ ) !Prepaid sales and marketing costs ~ g  ~ E  Prepaid insurance  ~ Ι   ~ ΄)  Other prepaid costs  ~ ((   ~   Prepaid vendor deposits   ?   ~ n ' TOTAL OTHER CURRENT ASSETS~ R*7~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|{oc514(=PF0*8X> @Z      l  q  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } I"} $ }  } $ }  } $                         TherapeuticsMD, Inc. 10-Q 05/07/2018 NOTE 6 FIXED ASSETS, NET March 31, December 31,  ~   ~  Accounting system ~ `  ~ `   Equipment  ~ vV   ~   Furniture and fixtures  ~    ~   Computer hardware  ~ N   ~ N Leasehold improvements~ P~ P~ Z 3~ d1 Accumulated depreciation~ ~ H$ TOTAL FIXED ASSETS, NET~ ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2~rfHIBJ=PF0*8X> @Z      l  &  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NET!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } a/} $ }  } $ }  }  $ } y} $ }  } $      TherapeuticsMD, Inc. 10-Q 05/07/2018 NOTE 7 INTANGIBLE ASSETSMarch 31, 2018   Gross Carrying Amount   Accumulated Amortization   Net   Weighted- Average            Amount  , $Remaining Amortization Period (yrs.)& Amortizable intangible assets:                 OPERA ? software patent ~ >  ~ s  ~ f    '@ . &Development costs of corporate website  ~ ~   ~ f    ?    n/a /'Approved hormone therapy drug candidate~ IV~ ~>  ~  jJ  -@patents.&Hormone therapy drug candidate patents~ j ?  ~  j   n/a (pending)*"Non-amortizable intangible assets:     Multiple trademarks~ : ?  ~  :   indefinite Total~ z~  ~  :  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 ~rf(Ky =PF0*8X> @       l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } a/} $ }  } $ }  }  $ } y} $ }  } $      TherapeuticsMD, Inc. 10-Q 05/07/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTSDecember 31, 2017   Gross Carrying Amount   Accumulated Amortization   Net   Weighted- Average            Amount  , $Remaining Amortization Period (yrs.)& Amortizable intangible assets:                 OPERA ? software patent ~ >  ~ f{  ~ n    '@ . &Development costs of corporate website  ~ ~   ~ f    ?    n/a /'Approved hormone therapy drug candidate~ N~   ~  vD  ~ >patents.&Hormone therapy drug candidate patents~ fi ?  ~  fi   n/a (pending)*"Non-amortizable intangible assets:     Multiple trademarks~ < ?  ~  <   indefinite Total~ ~ c ~  1  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 nbVJ ,Zp=PF0*8X> @       l  h  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } $ } } $      TherapeuticsMD, Inc. 10-Q 05/07/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Year Ending Estimated  December 31,    Amortization  2018(9 months)  ~   ~   ~ ,  ~   ~ ,  ~   ~ , ~ ~ , Thereafter~ Z3$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.wnbVJZv*=PF0*8X> @j        l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)NOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } 0} $ } y} $ } y} $                              TherapeuticsMD, Inc. 10-Q 05/07/2018( NOTE 8 OTHER CURRENT LIABILITIES March 31, December 31,  ~   ~ / 'Accrued payroll, bonuses and commission ~ 2  ~   costs) !Allowance for coupons and returns  ~ q   ~ :tW $ Accrued compensated absences  ~ ^:   ~ ƴ9 Other accrued expenses~ ~  Accrued rebates~ A~ ֱ,$Accrued legal and accounting expense~ r4~ z$)!Accrued sales and marketing costs~ 2p~  ( Accrued research and development~ ֩9~ Ve Accrued rent~ N~ 0(Allowance for wholesale distributor fees~ 6~  Accrued royalties~ ~ 'TOTAL OTHER CURRENT LIABILITIES~ *A<~ 2$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/< vj^*vcB.6*=PF0*8X> @Z      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } m} $ } } $ } } $                    TherapeuticsMD, Inc. 10-Q 05/07/2018!NOTE 9 NET LOSS PER SHAREThree months ended   March 31, 2018   March 31, 2017   Stock options  ~ 2   ~ VR  Warrants  ~ f   ~ .y    ~    ~ 2  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(T}qe#6NB6=PF0*8X> @2   l  P  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } U} <} $ } <      TherapeuticsMD, Inc. 10-Q 05/07/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Three Months Three Months  Ended  Ended   March 31,   March 31, ~  ~  Risk-free interest rate  2.38-2.60%  1.90%  Volatility  63.59-64.04%   61.56-62.83%Term (in years)6-6.256-6.25Dividend yield 0.00% 0.00%$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.6nbVJR_ =PF0*8X> @ l  q  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } 0} $ } }  $ } } $      TherapeuticsMD, Inc. 10-Q 05/07/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS1)Number of Shares Underlying Stock Options'Weighted Average Exercise Price  Weighted  !Aggregate Intrinsic Value           Average            Remaining            Contractual            Life in Years$ Balance at December 31, 2017  ~    = ףp=@    Q@  ~ j  Granted~ r{(\@      Exercised~ f(\?     ~ b0 Expired/Forfeited~ @     !Balance at March 31, 2018~ 2HzG@   333333@  ~  0(Vested and Exercisable at March 31, 2018~ r333333 @   @  ~ :Y "Unvested at March 31, 2018~ H.(\@   333333"@  ~ ҆$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6 nbVJE- -[=PF0*8X> @     l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } $ } I"} $ } y} $      TherapeuticsMD, Inc. 10-Q 05/07/2018<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS!Years Ending December 31,  2018 (9 months)  ~ X,  ~    ~ B  ~    ~ C  ~    ~ ^9  ~     ? $Total minimum lease payments~ *$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,b|nbVJD==PF0*8X> @2  l  'r  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } $}  } m} <} m}  '     TherapeuticsMD, Inc. 10-Q 05/07/2018 Research and Development6.Replenish Trial Co-Primary Efficacy Endpoints:0 (Mean Change in Frequency and Severity of4 ,Hot Flashes Per Week Versus Placebo at Weeks% 4 and 12, VMS-MITT Population            Estradiol/Progesterone 1 mg/100 mg 0.5 mg/100 mg 0.5 mg/50 mg 0.25 mg/50 mgPlacebo (n = 141) (n = 149) (n = 147) (n = 154) (n = 135) Frequency%Week 4 P-value versus placebo9v??5^I ?MbP? ?&Week 12 P-value versus placeboMb`? ?Severity%Week 4 P-value versus placeboX9v?{Gzt?Dl?? ?&Week 12 P-value versus placebo;On?~jt? ?0(Replenish Trial Primary Safety Endpoint:6.Incidence of Consensus Endometrial Hyperplasia2*or Malignancy up to 12 months, EndometrialSafety Population?Dm l~rf,Oqlg !"#$%&      !Endometrial Hyperplasia! 0% (0/280)! 0% (0/303)! 0% (0/306)! 0% (0/274)! 0% (0/92)"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/ x(=PF0*8X> @Z &&%%$$    l  q   dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and DevelopmentResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } $} $ }  } $ }  } $                        TherapeuticsMD, Inc. 10-Q 05/07/2018)!Research and Development ExpensesThree Months Ended    March 31,  ~   ~      (000s)   TX 001-HR ~ f4  ~ "7   TX 002-HR   ?    ?  TX 004-HR~ ~ f&Other research and development~ #~ 2# Total~ m~ x$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0Iui]T|u =PF0*8X> @b        l  -  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } } $ } U} $ } U}  $ } U} $                         TherapeuticsMD, Inc. 10-Q 05/07/2018Results of OperationsThree Months Ended       March 31,  ~   ~    Change    (000s)   Revenues, net ~ :  ~ F>  ~   Cost of goods sold  ~     ~ N    ~  Operating expenses~ B~   ~  2  Operating loss~ }~ j  ~  f Other income, net~ ~    ~   Net loss~ ~ r ~  J $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/28uiT+v=1%=PF0*8X> @z          l  :  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } 2} $ }  } $} $ }  } $                          TherapeuticsMD, Inc. 10-Q 05/07/2018Results of OperationsThree Months Ended    March 31,  ~   ~  & Research and development costs   L9@ %   ffffff?@ %/ 'Human resource related costs, including  ~ ^ %  ~ ^ %$ salaries, benefits and taxes2*Sales and marketing costs, excluding humanB@ %L?@ %resource costs/'Professional fees for legal, accounting@ %@ %and consulting Other operating expensesffffff@ %333333@ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4Kui' qI>2&=PF0*8X> @:    l  G  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } 7} $ }  } $ }  }  $ } U} $                           TherapeuticsMD, Inc. 10-Q 05/07/2018Results of OperationsThree Months Ended       March 31,  ~   ~    Change    (000s) & Research and development costs ~ m  ~ x  ~ J % Human resources related costs  ~ Jd   ~ X   ~   6.Sales and marketing, excluding human resources~ ~ Nx  ~  +  costs/'Professional fees for legal, accounting~ ~   ~   and consulting Other operating expenses~  ~   ~    Total operating expenses~ B~  ~  2 $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6uiTEo=PF0*8X> @z          l  Q  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)Item 6 Exhibits SIGNATURES Exhibit 311 Exhibit 312U } 1} $                      TherapeuticsMD, Inc. 10-Q 05/07/2018'Liquidity and Capital ResourcesThree Months Ended    March 31,  ~   ~     (000s) - %Net cash used in operating activities ~   ~ J - %Net cash used in investing activities ~ 2  ~  1)Net cash provided by financing activities~ ~ r)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,R|wk_bh=PF0*8X> @r         l   b  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital Resources SIGNATURES Exhibit 311 Exhibit 312U } $ } y } $ }  } $ } 6      TherapeuticsMD, Inc. 10-Q 05/07/2018Item 6. ExhibitsExhibit Date Description  31.1*   May 7, 2018 0 (Certification of Chief Executive Officer     5 -pursuant to Rule 13a-14(a) and Rule 15d-14(a)  31.2*   May 7, 2018 0 (Certification of Chief Financial Officer     5 -pursuant to Rule 13a-14(a) and Rule 15d-14(a)  32.1*   May 7, 2018 5 -Section 1350 Certification of Chief ExecutiveOfficer 32.2* May 7, 20185-Section 1350 Certification of Chief FinancialOfficer101.INS* n/aXBRL Instance Document101.SCH* n/a/'XBRL Taxonomy Extension Schema Document101.CAL* n/a4,XBRL Taxonomy Extension Calculation LinkbaseDocument101.DEF* n/a3+XBRL Taxonomy Extension Definition LinkbaseInstance Document101.LAB* n/a.&XBRL Taxonomy Extension Label LinkbaseInstance Document101.PRE* n/a,$XBRL Taxonomy Extension Presentation"Linkbase Instance Document$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/D lzn&R~N|#J>2 =PF0*8X> @ l  +m  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits Exhibit 311 Exhibit 312U } $ } } U5      TherapeuticsMD, Inc. 10-Q 05/07/2018 SIGNATURES  THERAPEUTICSMD, INC.     By: /s/ Robert G. Finizio   Robert G. Finizio   Chief Executive Officer%(Principal Executive Officer) By:!/ s/ Daniel A. CartwrightDaniel A. CartwrightChief Financial Officer4,(Principal Financial and Accounting Officer)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8tP$Tw<=PF0*8X> @"  l  /{  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 312U } $ } } 8 /     TherapeuticsMD, Inc. 10-Q 05/07/2018 Exhibit 31.1 (a)-%Designed such disclosure controls and  - %procedures, or caused such disclosure  . &controls and procedures to be designed  6 .under our supervision, to ensure that material  / 'information relating to the registrant,  0 (including its consolidated subsidiaries,2*is made known to us by others within those0(entities, particularly during the period/'in which this report is being prepared; (b)5-Designed such internal control over financial2*reporting, or caused such internal control/'over financial reporting to be designed4,under our supervision, to provide reasonable.&assurance regarding the reliability of/'financial reporting and the preparation5-of financial statements for external purposes-%in accordance with generally acceptedaccounting principles; (c)7/Evaluated the effectiveness of the registrant?s.&disclosure controls and procedures and0(presented in this report our conclusions1)about the effectiveness of the disclosure1)controls and procedures, as of the end of/'the period covered by this report basedD2 l~r&A\q#>Y3 !"#$%&'()*+,-.   on such evaluation; and! !(d)2!*Disclosed in this report any change in the""4",registrant?s internal control over financial##7#/reporting that occurred during the registrant?s$$4$,most recent fiscal quarter (the registrant?s%%6%.fourth fiscal quarter in the case of an annual&&-&%report) that has materially affected,''5'-or is reasonably likely to materially affect,((.(&the registrant?s internal control over)) )financial reporting; and*+$,____________________________1-)Created by Morningstar Document Research.0.(http://documentresearch.morningstar.com/"t$/K=PF0*8X> @..--,, l  /  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NANA (1) Balance SheetIncome Statement Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS NETNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTES TO UNAUDITED CONSOLID (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARE!NOTES TO UNAUDITED CONSOLID (2)!NOTES TO UNAUDITED CONSOLID (3)!NOTES TO UNAUDITED CONSOLID (4)Research and Development!Research and Development ExpensResults of OperationsResults of Operations (1)Results of Operations (2)!Liquidity and Capital ResourcesItem 6 Exhibits SIGNATURES Exhibit 311U } $ } } 8 /     TherapeuticsMD, Inc. 10-Q 05/07/2018 Exhibit 31.2 (a)-%Designed such disclosure controls and  - %procedures, or caused such disclosure  . &controls and procedures to be designed  6 .under our supervision, to ensure that material  / 'information relating to the registrant,  0 (including its consolidated subsidiaries,2*is made known to us by others within those0(entities, particularly during the period/'in which this report is being prepared; (b)5-Designed such internal control over financial2*reporting, or caused such internal control/'over financial reporting to be designed4,under our supervision, to provide reasonable.&assurance regarding the reliability of/'financial reporting and the preparation5-of financial statements for external purposes-%in accordance with generally acceptedaccounting principles; (c)7/Evaluated the effectiveness of the registrant?s.&disclosure controls and procedures and0(presented in this report our conclusions1)about the effectiveness of the disclosure1)controls and procedures, as of the end of/'the period covered by this report basedD2 l~r&A\q#>Y3 !"#$%&'()*+,-.   on such evaluation; and! !(d)2!*Disclosed in this report any change in the""4",registrant?s internal control over financial##7#/reporting that occurred during the registrant?s$$4$,most recent fiscal quarter (the registrant?s%%6%.fourth fiscal quarter in the case of an annual&&-&%report) that has materially affected,''5'-or is reasonably likely to materially affect,((.(&the registrant?s internal control over)) )financial reporting; and*+$,____________________________1-)Created by Morningstar Document Research.0.(http://documentresearch.morningstar.com/"t$/K=PF0*8X> @..--,, Root Entry FBook  $  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~